VRTX

Q: What is the price of Vertex Pharmaceuticals (VRTX) today?

The price of Vertex Pharmaceuticals (VRTX) today is US$ 407,79, with a variation of -14.36% compared to the last year. The price of Vertex Pharmaceuticals (VRTX) started the year trading around US$ 402,70 and today it is at US$ 407,79. Follow the real-time price chart, the historical price of Vertex Pharmaceuticals (VRTX), and stock data from Ibovespa and international markets.

Q: When does Vertex Pharmaceuticals (VRTX) pay dividends?

Vertex Pharmaceuticals (VRTX) did not distribute dividends in the last year.

Q: Vertex Pharmaceuticals (VRTX) is it worth it?

Currently, Vertex Pharmaceuticals (VRTX) is priced at US$ 407,79, with a P/E of 28,59%, representing a deviation of 17,48% from its historical average P/E. In the last year, the stock showed a variation of -14.36% in its price and distributed US$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was -14,36%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How to buy stocks of Vertex Pharmaceuticals (VRTX)?

Investing in stocks of Vertex Pharmaceuticals (VRTX) can be done in two ways: by buying the stock no exterior. A stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much do 100 stocks of Vertex Pharmaceuticals (VRTX) yield today?

The yield of Vertex Pharmaceuticals (VRTX) was 4,95% in the last month, -14,36% in the last year and 48,50% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of US$ 0,00 in dividends, um Dividend Yield de 0,00%.If you wanted to buy 100 stocks of Vertex Pharmaceuticals (VRTX) today, the total investment would be US$ 40.779,00, based on the current price of US$ 407,79.If past performance were to repeat, the return on your investment would be:In 1 year: US$ 34.923,14In 5 years: US$ 60.556,82In 10 years: 146.771,78It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Vertex Pharmaceuticals Incorporated

Price

US$ 407,79

variation (12m)

-14,36%

p/l

28,59

p/vp

6,03

DIVIDEND YIELD

0,00%

price VRTX

BVMF

VRTX

If you had invested

years ago

6 months

1 year

5 years

10 years

ago, today you would have

ago, today you would have:

*The figure considers the reinvestment of dividends.

Profitability of VRTX

1 month

3 months

1 year

2 years

5 years

10 years

profitability

1 month

4,95%

3 months

-13,02%

1 year

-14,36%

2 years

10,81%

5 years

48,50%

10 years

259,92%

real profitability

profitability minus inflation.

1 month

4,95%

3 months

-13,34%

1 year

-18,12%

2 years

1,14%

5 years

9,74%

10 years

115,49%

Indicators VRTX

check out the fundamentals of Vertex Pharmaceuticals shares

P/E

28,59

Sector: -3,47 Industry: -3,47

P/SALES RATIO (PSR)

8,93

Sector: -4,23 Industry: -4,23

P/BV

6,03

Sector: 1,89 Industry: 1,89

DIVIDEND YIELD (DY)

0,00%

Sector: - Industry: -

ROA

15,08%

Sector: -63,87% Industry: -63,87%

ROE

21,11%

Sector: -70,87% Industry: -70,87%

ROIC

27,21%

Sector: -2.084,36% Industry: -2.084,36%

NET MARGIN

31,22%

Sector: -41,75% Industry: -41,75%

GROSS MARGIN

86,21%

Sector: 38,19% Industry: 38,19%

OPERATING MARGIN

38,34%

Sector: -41,04% Industry: -41,04%

P/EBITDA

22,82

Sector: -3,65 Industry: -3,65

P/EBIT

23,31

Sector: -3,64 Industry: -3,64

P/ASSET

4,31

Sector: 1,41 Industry: 1,41

BVPS

66,83

Sector: 1,84 Industry: 1,84

EPS

14,11

Sector: -2,20 Industry: -2,20

EQUITY / ASSETS

0,71

Sector: 0,42 Industry: 0,42

CAGR REVENUES 5 YEARS

13,27%

Sector: - Industry: -

CAGR PROFITS 5 YEARS

5,48%

Sector: - Industry: -

FAIR PRICE OF Vertex Pharmaceuticals ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Price

The Fair Price formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

US$ 407,79

Fair Price

US$ 0,00

Upside Potencial de rentabilidade.

-64,28%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

VRTX indicators history

DRAG THE FRAME TO SEE MORE DATA

Stocks comparator

DRAG THE FRAME TO SEE MORE DATA

	p/l	p/vp	ROE	dy	market value	net margin
JNJ	17,80	5,78	32,50%	2,69%	US$ 453,87 B	27,75%
PFE	16,92	1,75	10,33%	6,25%	US$ 155,60 B	15,13%
ABBV	108,79	-2.966,40	-2.726,81%	2,79%	US$ 409,36 B	6,45%
NVO	16,20	10,21	62,99%	2,83%	US$ 265,17 B	34,74%
MRK	12,67	4,56	36,03%	3,59%	US$ 223,87 B	28,16%
AZN	28,39	5,90	20,79%	1,83%	US$ 264,46 B	16,23%
BMY	17,97	5,29	29,44%	5,41%	US$ 92,49 B	10,71%
GILD	19,99	7,16	35,82%	2,79%	US$ 140,30 B	24,71%
ZTS	24,61	13,09	53,20%	1,32%	US$ 65,16 B	28,00%
HALO	14,26	25,08	175,93%	0,00%	US$ 8,35 B	48,21%
REGN	13,97	2,10	15,06%	0,44%	US$ 63,00 B	31,83%
AMGN	30,70	21,58	70,29%	3,15%	US$ 160,26 B	14,67%
MCK	24,89	-106,90	-429,55%	0,40%	US$ 92,26 B	0,97%
CAH	26,56	-13,96	-52,54%	1,31%	US$ 36,76 B	0,60%
ADMA	17,05	8,87	52,03%	0,00%	US$ 3,53 B	43,51%
BIIB	13,23	1,33	10,08%	0,00%	US$ 23,50 B	17,46%
HRMY	8,91	2,01	22,58%	0,00%	US$ 1,55 B	22,19%

comparison of VRTX with indexes

If you had invested (change) 2 years years ago, ago, today you would have

R$ 1.000,00 in PETR4 you would have R$ 2.294,60

R$ 1.000,00 in LEVE3 you would have R$ 5.240,60

*The value considers the reinvestment of dividends.

Dividend History VRTX

current DY: 0,00%

5-year average DY: 0,00%

no dividend paid in the period.

ABOUT THE COMPANY Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated

Average user rating I10

5.0 (18 people)

Estados Unidos

36 years

Foundation: 1989

1991

Year of debut on the stock exchange - 34 years

3.400

Employees

The Company Vertex Pharmaceuticals Incorporated (Estados Unidos), is listed on Nasdaq with a market value of $ 103,65 Billions, having a net worth of $ 17,18 Billions.

With a total of 3.400 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 11,61 Billions, which generated a profit in the amount of $ 3,63 Billions.

As for its main indicators, the Company has a P/E ratio of 28,59, a P/BV ratio of 6,03 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker VRTX.

Market value

US$ 103,65 Billions

Net worth

US$ 17,18 Billions

US$ 17.175.400.000,00

Assets

US$ 24,04 Billions

US$ 24.036.700.000,00

Total Number of Shares

257,00 Milhões

257.000.000

Average Daily Trading Volume

US$ 2,01 Milhões

US$ 2.005.302,00

Sector

Health Care

Industry

Biotechnology

VRTX

VRTX revenue and profits

VRTX results

DRAG THE FRAME TO SEE MORE DATA

VRTX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

US$ - -0,00% (12M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 763,55 51,69% (12M)

P/L

24,89

0,40%

ROE

-429,55%

P/VP

-106,90

CAH - Cardinal Health

US$ 156,88 42,09% (12M)

P/L

26,56

1,31%

ROE

-52,54%

P/VP

-13,96

JNJ - Johnson & Johnson

US$ 190,72 21,94% (12M)

P/L

17,80

2,69%

ROE

32,50%

P/VP

5,78

MRK - Merck & Co.

US$ 85,99 --18,73% (12M)

P/L

12,67

3,59%

ROE

36,03%

P/VP

4,56

ABBV - AbbVie

US$ 230,50 23,82% (12M)

P/L

108,79

2,79%

ROE

-2.726,81%

P/VP

-2.966,40

PFE - Pfizer

US$ 24,78 --8,77% (12M)

P/L

16,92

6,25%

ROE

10,33%

P/VP

1,75

AZN - AstraZeneca

US$ 84,53 11,61% (12M)

P/L

28,39

1,83%

ROE

20,79%

P/VP

5,90

BFRA - Biofrontera

US$ - -0,00% (12 M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 763,55 51,69% (12 M)

P/L

24,89

0,40%

ROE

-429,55%

P/VP

-106,90

CAH - Cardinal Health

US$ 156,88 42,09% (12 M)

P/L

26,56

1,31%

ROE

-52,54%

P/VP

-13,96

JNJ - Johnson & Johnson

US$ 190,72 21,94% (12 M)

P/L

17,80

2,69%

ROE

32,50%

P/VP

5,78

MRK - Merck & Co.

US$ 85,99 --18,73% (12 M)

P/L

12,67

3,59%

ROE

36,03%

P/VP

4,56

ABBV - AbbVie

US$ 230,50 23,82% (12 M)

P/L

108,79

2,79%

ROE

-2.726,81%

P/VP

-2.966,40

PFE - Pfizer

US$ 24,78 --8,77% (12 M)

P/L

16,92

6,25%

ROE

10,33%

P/VP

1,75

AZN - AstraZeneca

US$ 84,53 11,61% (12 M)

P/L

28,39

1,83%

ROE

20,79%

P/VP

5,90

Frequently Asked Questions

What is the price of Vertex Pharmaceuticals (VRTX) today?

The price of Vertex Pharmaceuticals (VRTX) today is US$ 407,79, with a variation of -14.36% compared to the last year. The price of Vertex Pharmaceuticals (VRTX) started the year trading around US$ 402,70 and today it is at US$ 407,79. Follow the real-time price chart, the historical price of Vertex Pharmaceuticals (VRTX), and stock data from Ibovespa and international markets.

When does Vertex Pharmaceuticals (VRTX) pay dividends?

Vertex Pharmaceuticals (VRTX) did not distribute dividends in the last year.

Vertex Pharmaceuticals (VRTX) is it worth it?

Currently, Vertex Pharmaceuticals (VRTX) is priced at US$ 407,79, with a P/E of 28,59%, representing a deviation of 17,48% from its historical average P/E. In the last year, the stock showed a variation of -14.36% in its price and distributed US$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was -14,36%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How to buy stocks of Vertex Pharmaceuticals (VRTX)?

Investing in stocks of Vertex Pharmaceuticals (VRTX) can be done in two ways: by buying the stock no exterior. A stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much do 100 stocks of Vertex Pharmaceuticals (VRTX) yield today?

The yield of Vertex Pharmaceuticals (VRTX) was 4,95% in the last month, -14,36% in the last year and 48,50% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of US$ 0,00 in dividends, um Dividend Yield de 0,00%.

If you wanted to buy 100 stocks of Vertex Pharmaceuticals (VRTX) today, the total investment would be US$ 40.779,00, based on the current price of US$ 407,79.

If past performance were to repeat, the return on your investment would be:

In 1 year: US$ 34.923,14
In 5 years: US$ 60.556,82
In 10 years: 146.771,78

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

VRTX

Vertex Pharmaceuticals Incorporated

Price

variation (12m)

p/l

p/vp

DIVIDEND YIELD

Profitability of VRTX

check out the fundamentals of Vertex Pharmaceuticals shares

P/E

P/SALES RATIO (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSET

BVPS

EPS

EQUITY / ASSETS

CAGR REVENUES 5 YEARS

CAGR PROFITS 5 YEARS

Graham's Fair Price

If you had invested (change) 2 years years ago, ago, today you would have

current DY: 0,00%

5-year average DY: 0,00%

ABOUT THE COMPANY Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated

Estados Unidos

36 years

1991

3.400

PROFIT X PRICE VRTX

VRTX results

VRTX cash flow

evolution of assets - VRTX

VRTX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

Frequently Asked Questions